MedTrace Logo

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

NCT05897541 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2387

Last updated 2025-08-06

No results posted yet for this study

Summary

The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction \[RT-PCR\] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 tablets compared with placebo tablets in participants who are household contacts of an individual with symptomatic COVID-19.

Conditions

Interventions

DRUG

S-217622

Administered as a tablet.

DRUG

Placebo

Administered as a tablet.

Sponsors & Collaborators

  • Shionogi

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-09
Primary Completion
2024-08-30
Completion
2024-09-18
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Japan
  • South Africa
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05897541 on ClinicalTrials.gov